Circulating hs-CRP directly triggers CCR2+ monocyte recruitment to the CNS by enhancing CCL2 expression in brain endothelial cells and resident microglia through TLR4/MyD88 signaling. Once recruited, CCR2+ monocytes undergo rapid activation and begin secreting IL-1β, which creates a positive feedback loop by further stimulating microglial TLR4 receptors and promoting additional CCL2 release. This hs-CRP-initiated cascade fundamentally disrupts CNS immune privilege by establishing sustained peripheral immune cell infiltration rather than transient inflammatory responses. The hypothesis proposes that hs-CRP acts as the upstream molecular trigger that transforms the normally protective blood-brain barrier into a conduit for pathogenic monocyte invasion. Critical to this mechanism is that hs-CRP binding to microglial TLR4 receptors not only induces direct IL-1β secretion but simultaneously upregulates CCL2 production, creating a dual recruitment and activation signal.

Circulating hs-CRP directly triggers CCR2+ monocyte recruitment to the CNS by enhancing CCL2 expression in brain endothelial cells and resident microglia through TLR4/MyD88 signaling. Once recruited, CCR2+ monocytes undergo rapid activation and begin secreting IL-1β, which creates a positive feedback loop by further stimulating microglial TLR4 receptors and promoting additional CCL2 release. This hs-CRP-initiated cascade fundamentally disrupts CNS immune privilege by establishing sustained peripheral immune cell infiltration rather than transient inflammatory responses. The hypothesis proposes that hs-CRP acts as the upstream molecular trigger that transforms the normally protective blood-brain barrier into a conduit for pathogenic monocyte invasion. Critical to this mechanism is that hs-CRP binding to microglial TLR4 receptors not only induces direct IL-1β secretion but simultaneously upregulates CCL2 production, creating a dual recruitment and activation signal. The recruited CCR2+ monocytes then differentiate into a distinct pro-inflammatory phenotype that maintains chronic neuroinflammation through sustained IL-1β production, effectively converting the CNS from an immune-privileged site into an inflammatory tissue. This model predicts that therapeutic targeting of circulating hs-CRP levels would simultaneously reduce both the initial monocyte recruitment signal and the subsequent IL-1β amplification cascade, offering a dual mechanism for restoring CNS immune privilege. The hypothesis can be tested by measuring CCL2 expression in brain endothelium following hs-CRP exposure, tracking CCR2+ monocyte infiltration patterns in high hs-CRP conditions, and demonstrating that hs-CRP depletion reduces both monocyte recruitment and microglial IL-1β production in neuroinflammatory models.